BUZZ-UniQure triples after brain disorder therapy slows disease progression in trial

Reuters

Sep 25, 2025

Updates

** U.S.-listed shares of uniQure UQ1.F, QURE.O more than triple to a near five-year high of $47.37

** Stock set for its best day ever, if gains hold

** The Netherlands-based drugmaker says its experimental gene therapy significantly slowed progression of a brain disorder in early-to-mid stage study

** QURE is developing a therapy called AMT-130 to treat Huntington's disease, a rare inherited brain disorder that progressively impairs movement, thinking, and behavior, ultimately leading to severe disability and death

** Separately, QURE says it secured a $175 million loan from Hercules Capital HTGC.N to support the potential U.S. launch of AMT-130

** Including session's move, stock up 162.1% YTD

(Reporting by Puyaan Singh and Lance Tupper)

((Puyaan.Singh@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2570862770"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570862770\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570862770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570862770","market":"nz","top_or_hot":-1,"title":"BUZZ-UniQure triples after brain disorder therapy slows disease progression in trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-UniQure triples after brain disorder therapy slows disease progression in trial</title></head><body>Updates** U.S.-listed shares of uniQure UQ1.F, QURE.O more than triple to a near five-year high of $47.37** Stock set for its best day ever, if gains hold** The Netherlands-based drugmaker says its experimental gene therapy significantly slowed progression of a brain disorder in early-to-mid stage study\n ** QURE is developing a therapy called AMT-130 to treat Huntington's disease, a rare inherited brain disorder that progressively impairs movement, thinking, and behavior, ultimately leading to severe disability and death\n\n ** Separately, QURE says it secured a $175 million loan from Hercules Capital HTGC.N to support the potential U.S. launch of AMT-130** Including session's move, stock up 162.1% YTD(Reporting by Puyaan Singh and Lance Tupper)((Puyaan.Singh@thomsonreuters.com;))</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-UniQure triples after brain disorder therapy slows disease progression in trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-UniQure triples after brain disorder therapy slows disease progression in trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2025-09-25 00:34\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-UniQure triples after brain disorder therapy slows disease progression in trial</title></head><body>Updates** U.S.-listed shares of uniQure UQ1.F, QURE.O more than triple to a near five-year high of $47.37** Stock set for its best day ever, if gains hold** The Netherlands-based drugmaker says its experimental gene therapy significantly slowed progression of a brain disorder in early-to-mid stage study\n ** QURE is developing a therapy called AMT-130 to treat Huntington's disease, a rare inherited brain disorder that progressively impairs movement, thinking, and behavior, ultimately leading to severe disability and death\n\n ** Separately, QURE says it secured a $175 million loan from Hercules Capital HTGC.N to support the potential U.S. launch of AMT-130** Including session's move, stock up 162.1% YTD(Reporting by Puyaan Singh and Lance Tupper)((Puyaan.Singh@thomsonreuters.com;))</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4135","symbol_name":"资产管理与托管银行","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nL3N3VB167:1","article_id":"2570862770","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570862770","pubTimestamp":1758731695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-UniQure triples after brain disorder therapy slows disease progression in trialUpdates** U.S.-listed shares of uniQure UQ1.F, QURE.O more than triple to a near five-year high of $47.37** Stock set for its best day ever, if gains hold** The Netherlands-based drugmaker says its experimental gene therapy significantly slowed progression of a brain disorder in early-to-mid stage study. ** QURE is developing a therapy called AMT-130 to treat Huntington's disease, a rare inherited brain disorder that progressively impairs movement, thinking, and behavior, ultimately leading to severe disability and death. ** Separately, QURE says it secured a $175 million loan from Hercules Capital HTGC.N to support the potential U.S. launch of AMT-130** Including session's move, stock up 162.1% YTD","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4135":"资产管理与托管银行","HTGC":"海格投资"},"translate_title":"BUZZ-UniQure在试验中脑部疾病治疗减缓疾病进展后增加了两倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HTGC":0.9},"content_text":"BUZZ-UniQure triples after brain disorder therapy slows disease progression in trialUpdates** U.S.-listed shares of uniQure UQ1.F, QURE.O more than triple to a near five-year high of $47.37** Stock set for its best day ever, if gains hold** The Netherlands-based drugmaker says its experimental gene therapy significantly slowed progression of a brain disorder in early-to-mid stage study\n ** QURE is developing a therapy called AMT-130 to treat Huntington's disease, a rare inherited brain disorder that progressively impairs movement, thinking, and behavior, ultimately leading to severe disability and death\n\n ** Separately, QURE says it secured a $175 million loan from Hercules Capital HTGC.N to support the potential U.S. launch of AMT-130** Including session's move, stock up 162.1% YTD(Reporting by Puyaan Singh and Lance Tupper)((Puyaan.Singh@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}